Metamizole is not listed as a drug with DDI potential in the summary of product characteristics; however, the University of Liverpool hepatitis drug checker describes a possibility of decreased concentration of SOF/VEL, GLE/PIB or EBR/GZR due to induction of CYP3A4 by metamizole. The gene discussed is CYP3A4; the disease is hepatitis A virus infection.